Baxalta Brooklyn Park
Successful Pharma Facility Real Estate Transaction
Baxalta U.S. Inc. retained PharmBioSource Realty, LLC as its exclusive real estate broker to market and sell its 215,000 SF mammalian cell culture manufacturing facility located in Brooklyn Park, Minnesota.
Baxalta had recently formed as a spin-out of Baxter International and as part of its manufacturing site network consolidation plan, Baxalta made the strategic decision to divest the biologics API facility that it had acquired from Genmab in 2013. PharmaBioSource Realty had also been the broker on that transaction.
The facility represented an excellent opportunity for a buyer to acquire a significant biologics API manufacturing asset at a discount and with a significant reduction in time to market.
To assist Baxalta with its goal of divesting its Brooklyn Park, MN facility, PharmaBioSource Realty engaged the pharmaceutical and biotech industry to market and sell the facility to a strategic acquirer.
We utilized our real estate and technical expertise and extensive contacts within the Life Sciences Industry to identify a number of potential buyers for the Brooklyn Park facility. The facility housed 22,000 L of bioreactor capacity and was located on 29 acres 10 miles north of Minneapolis.
Services provided by PharmaBioSource experts:
PharmaBioSource Realty, LLC solicited multiple offers for the Baxalta facility and ultimately identified Takeda, a research-based global company with its main focus on pharmaceuticals and the largest pharmaceutical company in Japan, as the acquirer. The transaction represented a significant value for Baxalta and the entire deal was completed in just 7 months.